



RECEIVED

MAY 08 2003

DOCKET NO.: PRD-0003/ORT-1060

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, et al.

Confirmation No.: 4589

Application No.: 09/434,965

Group Art Unit: 4589


Filing Date: November 5, 1999

Examiner: DeCloux, Amy M.

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

DATE OF DEPOSIT: May 2, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, DC 20231.

  
TYPED NAME: Felicity E. Groth  
REGISTRATION NO.: 47,042

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☒ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:

☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .


☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated **October 29, 1997** and a copy of the EPO European Search Report dated **May 21, 2002**, which indicates the references to be relevant.

There are no listed references which are not in the English language.

Date: *May 2, 2003*

  
\_\_\_\_\_  
**Felicity E. Groth**  
Registration No. 47,042

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

**RECEIVED**

MAY 08 2003

TECH CENTER 1600/2900

Sheet 2 of 2

**Form PTO-1449 Modified**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
**PRD-0003/ORT-1060**Application No.  
**09/434,965**Applicant  
**Alain T. Luxembourg, et al.**Filing Date  
**November 5, 1999**Group  
**4589****U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	59	5,045,320	09/03/91	Mescher	424	450
	60	5,529,921	06/25/96	Peterson, et al.	435	240.2

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	61	CA 2 069 541	11/27/93	Canada		
	62	EP 0 814 838	01/07/98	EPO		
	63	WO 96/05287	02/22/96	PCT		
	64	WO 96/27392	09/12/96	PCT		

**EXAMINER****DATE CONSIDERED**

**RECEIVED**

MAY 08 2003

TECH CENTER 1600/2900

Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>PRD-0003/ORT-1060</b>	Application No. <b>09/434,965</b>
		Applicant <b>Alain T. Luxembourg, et al.</b>	
		Filing Date <b>November 5, 1999</b>	Group <b>4589</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>56</b>	Luxembourg, A.T. et al., "Biomagnetic Isolation of Antigen-Specific CD8 + T Cells Usuable in Immunotherapy", <i>Nature Biotechnology</i> , <b>1998</b> , 16(3), 281-285, XP-002198433	
	<b>57</b>	Nag, B. et al., "Stimulation of T Cells by Antigenic Peptide Complexed with Isolated Chains of Major Histocompatibility Complex Class II Molecules", <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90(4), 1604-1608	
	<b>58</b>	Stryhn, A. et al., "Preformed Purified Peptide/Major Histocompatibility Class I Complexes are Potent Stimulators of Class I-Restricted T Cell Hybridomas", <i>Eur. J. Immunol</i> , <b>1994</b> , 24(6), 1404-1409, XP-008003084	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	